...
首页> 外文期刊>Regulatory Toxicology and Pharmacology: RTP >On the safety of a new generation of DSM Aspergillus niger enzyme production strains.
【24h】

On the safety of a new generation of DSM Aspergillus niger enzyme production strains.

机译:关于新一代DSM黑曲霉酶生产菌株的安全性。

获取原文
获取原文并翻译 | 示例
           

摘要

Consumers safety of enzyme preparations is determined by three variables: the producing organism, the raw materials used in the production, and the production process itself. The latter one is embedded in current Good Manufacturing Practice (cGMP) and Hazard Analysis of Critical Control Points (HACCP); therefore the safety focus can be directed to raw materials and the producing organism. In this paper, we describe the use of novel genetically modified strains of Aspergillus niger-made by a design and build strategy-from a lineage of classically improved strains with a history of safe use in enzyme production. The specifics of the host strain allow for integration and over-expression of any gene of interest at a targeted integration site implying that the rest of the host genome is not affected by this integration. Furthermore due to the fact that the newly integrated gene copies are put under the genetic regulation of the host's own glucoamylase promoter, the recipe of the production process of any new production strain can be kept constant with respect to the raw materials composition. Consequently the safety of a new enzyme product from these novel genetically modified strains is determined by the background of the production organism. The use of a strain with a history of safe use and targeted integration according to the concept described above has consequences for the safety studies on the final product. If a known enzymatic activity is over-expressed the safety of a new enzyme preparation is covered by the results of the safety studies performed for other strains from this specific Aspergillus niger strain lineage. In this paper an overview is given on the available toxicity tests with these strains. We conclude that for new enzyme products produced with strains from this lineage using the design and build technology no new sub-acute/chronic oral toxicity studies are needed. This also has the benefit that no longer test animals are needed to demonstrate the safety of products produced by these strains.
机译:消费者对酶制剂的安全性取决于三个变量:生产生物,生产中使用的原材料以及生产过程本身。后者嵌入在当前的良好生产规范(cGMP)和关键控制点危害分析(HACCP)中;因此,安全重点可以放在原材料和生产生物上。在本文中,我们描述了通过设计和构建策略制备的新型黑曲霉基因改造菌株的使用,该菌株来自具有酶生产安全使用历史的经典改良菌株。宿主菌株的特异性允许在目标整合位点整合和过量表达任何目的基因,这意味着宿主基因组的其余部分不受该整合的影响。此外,由于将新整合的基因拷贝置于宿主自己的葡糖淀粉酶启动子的遗传调控下,因此任何新生产菌株的生产过程的配方相对于原料组成可以保持恒定。因此,由这些新的基因修饰菌株产生的新酶产品的安全性取决于生产生物的背景。根据上述概念使用具有安全使用和针对性整合历史的菌株,会对最终产品的安全性研究产生影响。如果过分表达了已知的酶活性,则针对该特定黑曲霉菌株谱系的其他菌株进行的安全性研究结果将涵盖新酶制剂的安全性。本文概述了这些菌株的可用毒性试验。我们得出的结论是,使用设计和构建技术从该谱系菌株生产的新酶产品不需要新的亚急性/慢性口服毒性研究。这还具有以下优点:不再需要测试动物来证明由这些菌株产生的产品的安全性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号